Using MRI radiomics to predict the efficacy of immunotherapy for brain metastasis in patients with small cell lung cancer
© 2024 The Authors. Thoracic Cancer published by John Wiley & Sons Australia, Ltd..
BACKGROUND: Brain metastases (BMs) are common in small cell lung cancer (SCLC), and the efficacy of immune checkpoint inhibitors (ICIs) in these patients is uncertain. In this study we aimed to develop and validate a radiomics nomogram based on magnetic resonance imaging (MRI) for intracranial efficacy prediction of ICIs in patients with BMs from SCLC.
METHODS: The training and validation cohorts consisted of 101 patients from two centers. The interclass correlation coefficient (ICC), logistic univariate regression analysis, and random forest were applied to select the radiomic features, generating the radiomics score (Rad-score) through the formula. Using multivariable logistic regression analysis, a nomogram was created by the combined model. The discrimination, calibration, and clinical utility were used to assess the performance of the nomogram. Kaplan-Meier curves were plotted based on the nomogram scores.
RESULTS: Ten radiomic features were selected for calculating the Rad-score as they could differentiate the intracranial efficacy in the training (area under the curve [AUC], 0.759) and the validation cohort (AUC, 0.667). A nomogram was created by combining Rad-score, treatment lines, and neutrophil-to-lymphocyte ratio (NLR). The training cohort obtained an AUC of 0.878 for the combined model, verified in the validation cohort (AUC = 0.875). Kaplan-Meier analyses showed the nomogram was associated with progression-free survival (PFS) (p = 0.0152) and intracranial progression-free survival (iPFS) (p = 0.0052) but not overall survival (OS) (p = 0.4894).
CONCLUSION: A radiomics nomogram model for predicting the intracranial efficacy of ICIs in SCLC patients with BMs can provide suggestions for exploring individual-based treatments for patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Thoracic cancer - 15(2024), 9 vom: 29. März, Seite 738-748 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shi, Xiaonan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Immune checkpoint inhibitors |
|---|
| Anmerkungen: |
Date Completed 26.03.2024 Date Revised 27.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/1759-7714.15259 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368669130 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368669130 | ||
| 003 | DE-627 | ||
| 005 | 20240327235842.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240220s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/1759-7714.15259 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1351.xml |
| 035 | |a (DE-627)NLM368669130 | ||
| 035 | |a (NLM)38376861 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shi, Xiaonan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Using MRI radiomics to predict the efficacy of immunotherapy for brain metastasis in patients with small cell lung cancer |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.03.2024 | ||
| 500 | |a Date Revised 27.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 The Authors. Thoracic Cancer published by John Wiley & Sons Australia, Ltd. | ||
| 520 | |a BACKGROUND: Brain metastases (BMs) are common in small cell lung cancer (SCLC), and the efficacy of immune checkpoint inhibitors (ICIs) in these patients is uncertain. In this study we aimed to develop and validate a radiomics nomogram based on magnetic resonance imaging (MRI) for intracranial efficacy prediction of ICIs in patients with BMs from SCLC | ||
| 520 | |a METHODS: The training and validation cohorts consisted of 101 patients from two centers. The interclass correlation coefficient (ICC), logistic univariate regression analysis, and random forest were applied to select the radiomic features, generating the radiomics score (Rad-score) through the formula. Using multivariable logistic regression analysis, a nomogram was created by the combined model. The discrimination, calibration, and clinical utility were used to assess the performance of the nomogram. Kaplan-Meier curves were plotted based on the nomogram scores | ||
| 520 | |a RESULTS: Ten radiomic features were selected for calculating the Rad-score as they could differentiate the intracranial efficacy in the training (area under the curve [AUC], 0.759) and the validation cohort (AUC, 0.667). A nomogram was created by combining Rad-score, treatment lines, and neutrophil-to-lymphocyte ratio (NLR). The training cohort obtained an AUC of 0.878 for the combined model, verified in the validation cohort (AUC = 0.875). Kaplan-Meier analyses showed the nomogram was associated with progression-free survival (PFS) (p = 0.0152) and intracranial progression-free survival (iPFS) (p = 0.0052) but not overall survival (OS) (p = 0.4894) | ||
| 520 | |a CONCLUSION: A radiomics nomogram model for predicting the intracranial efficacy of ICIs in SCLC patients with BMs can provide suggestions for exploring individual-based treatments for patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Radiomics | |
| 650 | 4 | |a immune checkpoint inhibitors | |
| 650 | 4 | |a nomogram | |
| 650 | 4 | |a prediction | |
| 650 | 4 | |a small cell lung cancer | |
| 700 | 1 | |a Wang, Peiliang |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yikun |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Junhao |e verfasserin |4 aut | |
| 700 | 1 | |a Yin, Tianwen |e verfasserin |4 aut | |
| 700 | 1 | |a Teng, Feifei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Thoracic cancer |d 2010 |g 15(2024), 9 vom: 29. März, Seite 738-748 |w (DE-627)NLM251832414 |x 1759-7714 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2024 |g number:9 |g day:29 |g month:03 |g pages:738-748 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/1759-7714.15259 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2024 |e 9 |b 29 |c 03 |h 738-748 | ||